| Arthritis is one of the most prevalent chronic health problems in the United States, not only in humans, but with different species as well. The purpose of this study is to evaluate the therapeutic efficacy and safety of Crominex 3+ in moderately arthritic canines. Eleven moderately arthritic canines were administered 10mg of Crominex 3+ twice daily for a total of 150 days. Nine of the canines participated in the treated group and received Crominex 3+ while the other two canines received a placebo. Each month on days 0, 30, 60, 90,120, and 150 each canine was observed for overall pain levels, pain upon limb manipulation, and pain after physical exertion. Radiographs were also performed on days 0 and 150 to observe if osteophyte formations could be reduced. A safety evaluation was observed each month with serum chemistries to test liver, kidney, and heart muscle functions. Body weight, heart rate, respiration rate, and temperature were also evaluated for any negative changes throughout the entire study.;Ultimately the nine treated canines exhibited a significant reduction in pain levels overall, during limb manipulation, and after physical exertion with P < 0.05. Serum chemistries presented with no side effects, and no significant changes in body weight, heart rate, respiration rate, body weight, or temperature were observed during the entire 150 days. The radiographs were unable to provide conclusive evidence that Crominex 3+ was able to reduce osteophytes in a 150 day period. Crominex 3+ has been proven safe and effective in reducing pain in moderately arthritic dogs, and may provide a safer alternative to NSAIDS or any other arthritic medications on the market today. |
